No Data
No Data
Fuan Pharmaceutical Subsidiary's Drug Passes Consistency Evaluation
Fuan Pharmaceutical (300194.SZ): The injection grade Cefozopran Sodium (1.0g) passed the generic drug quality and efficacy consistency evaluation.
On August 7, Gelunhui reported that Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. (referred to as "Qingyutang"), has recently received the drug supplementary application approval notice issued by the National Medical Products Administration. After review, the injectable Ceftriaxone Sodium ("Specification 1.0g") passed the generic drug quality and efficacy consistency evaluation. Injectable ceftriaxone is an antibacterial drug mainly used for lower respiratory tract infection, urinary tract infection, abdominal infection, pelvic infection, sepsis, skin soft tissue infection, bone and joint infection, pneumococcal or influenza pneumonia.
Fuan Pharmaceutical (300194.SZ): Cefoperazone sodium for injection passes the consistency evaluation of generic drug quality and efficacy.
On August 2, Gelonhui reported that Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Qingyutang Pharmaceutical Co., Ltd. (hereinafter referred to as 'Qingyutang'), recently received a notification of drug supplementary application approval issued by the National Medical Products Administration of China. After examination, injection of cephalosporin sodium passed the consistency evaluation of generic drug quality and efficacy. Cephalosporin sodium for injection is an anti-infective drug mainly used for lower respiratory tract infection, urinary tract infection, abdominal infection, pelvic infection, sepsis, soft tissue infection, bone and joint infection, pneumococcal or influenza bacteraemia, and meningitis.
As of July 31, the number of shareholders for Fuan Pharmaceutical (300194.SZ) was 40,774.
Fuan Pharmaceutical (300194.SZ) stated on the investor interaction platform on August 1 that as of July 31, the number of shareholders in the company was 40,774.
Fuan Pharmaceutical's Unit Gets Registration Certificate for Voriconazole for Injection
Fuan Pharmaceutical (300194.SZ): Zhichu Pharmaceutical has received the registration certificate of injection Voriconazole.
On July 24th, Gelunhui reported that Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Yantai Zhichu Pharmaceutical Co., Ltd. (referred to as 'Zhichu Pharmaceutical'), recently received a drug registration certificate issued by the National Medical Products Administration for injection of fluconazole. Injection of fluconazole is a broad-spectrum triazole antifungal drug, mainly used to treat fungal infections in adults and children aged 2 and above. According to the China National Medical Products Administration data query information platform, as of now, 18 enterprises (including Zhichu Pharmaceutical) have passed consistency evaluation or been deemed as equivalent.
No Data